Repairing Cells and Longevity Myths with Dr. Charles Brenner

Repairing Cells and Longevity Myths with Dr. Charles Brenner

Charles Brenner, a leading biochemist at City of Hope National Medical Center in L.A., discovered a vitamin precursor called NR that seems to enable repair of cellular damage that happens as we get older.

Charles Brenner

Meet Charles Brenner, the Longevity Skeptic. Brenner, a leading biochemist at City of Hope National Medical Center in L.A., has been attending the largest longevity conferences with one main purpose: to point out that some of the other speakers are full of it.

Brenner is "throwing cold water" on several scientists in the field of aging, accusing them of hyping various fountains of youth, despite limited evidence for these therapies.

In this podcast episode, Brenner sat down with Leaps.org to discuss his groundbreaking work on metabolism and his efforts to counter what he considers to be bad science.


Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.